Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Thirty-three-day storage of dithiothreitol-treated red blood cells used to eliminate daratumumab interference in serological testing

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Epidemiology of chronic red-cell transfusion recipients in Sweden and Denmark-a 10 year follow-up study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Iron deficiency and preoperative anaemia in patients scheduled for elective hip- and knee arthroplasty - an observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. New drug candidates for depression - a nationwide population-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pentaisomaltose, an Alternative to DMSO. Engraftment of Cryopreserved Human CD34+ Cells in Immunodeficient NSG Mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Restless legs syndrome is associated with major comorbidities in a population of Danish blood donors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Continuation of lithium after a diagnosis of chronic kidney disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND AND OBJECTIVES: Daratumumab binds CD38 on red blood cells causing interference with indirect antiglobulin tests. Dithiothreitol is used to eliminate interference allowing detection of alloantibodies. Haemolysis is observed during storage of dithiothreitol-treated antibody identification panel cells. The objective of this study was to develop a modified method for dithiothreitol treatment to reduce the haemolysis during 33 days of storage and still be able to eliminate daratumumab interference.

MATERIALS AND METHODS: Panel cells were treated with various volumes of 0·2 m dithiothreitol supplied by various manufacturers. Haemolysis Index of dithiothreitol-treated and untreated panel cells was measured and compared on days 1, 15 and 33. Antibody screening tests with dithiothreitol-treated screening cells were performed on samples from 15 daratumumab-treated patients (dose 16 mg/kg) and 34 patients with known alloantibodies. Antibody identifications with dithiothreitol-treated panel cells were performed on seven additional known alloantibodies.

RESULTS: Dithiothreitol treatment with a ratio of 30:25 (red blood cells:dithiothreitol) showed the same degree of haemolysis as with untreated panel cells. Daratumumab interference was eliminated in all 15 samples from daratumumab-treated patients. Twenty-six of 34 alloantibodies were detected, and all seven additional alloantibodies were identified using the modified dithiothreitol treatment. Eight alloantibodies within the Kell system were negative. No decrease in the reaction strength was observed during the 33-day storage period.

CONCLUSION: The modified dithiothreitol method was able to reduce haemolysis during storage and to detect and identify alloantibodies in the presence of daratumumab.

OriginalsprogEngelsk
TidsskriftVox Sanguinis
Vol/bind113
Udgave nummer7
Sider (fra-til)686-693
Antal sider8
ISSN0042-9007
DOI
StatusUdgivet - okt. 2018

Bibliografisk note

© 2018 International Society of Blood Transfusion.

ID: 57805264